

Elena Ratner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5400120/publications.pdf>

Version: 2024-02-01

59
papers

1,690
citations

279798

23
h-index

289244

40
g-index

59
all docs

59
docs citations

59
times ranked

2806
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Single application hybrid interstitial brachytherapy for cervical cancer: An institutional approach during the COVID-19 pandemic. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 66-71. | 0.9 | 4 |
| 2 | Randomised phase II trial of weekly ixabepilone±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. <i>British Journal of Cancer</i> , 2022, 126, 1695-1703. | 6.4 | 5 |
| 3 | A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218. | 4.1 | 28 |
| 4 | Financial toxicity in patients with gynecologic malignancies: a cross sectional study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e87. | 2.2 | 10 |
| 5 | Benefits of a Multidisciplinary Women's Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 143-149. | 1.3 | 4 |
| 6 | Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 48 |
| 7 | A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus <i>MLH</i>-1 methylated characteristics (NCT02899793).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5523-5523. | 1.6 | 5 |
| 8 | Serum-based assay for adnexal mass risk of ovarian malignancy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5551-5551. | 1.6 | 0 |
| 9 | Abstract 911:In vitroandin vivoactivity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. , 2021, , . | | 0 |
| 10 | Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. <i>Gynecologic Oncology</i> , 2021, 163, 93-99. | 1.4 | 14 |
| 11 | Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. <i>Human Pathology</i> , 2021, 118, 1-8. | 2.0 | 6 |
| 12 | Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. <i>Gynecologic Oncology</i> , 2021, 163, 557-562. | 1.4 | 4 |
| 13 | Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656. | 4.6 | 20 |
| 14 | Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118. | 2.8 | 30 |
| 15 | Risk-stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low-risk endometrial cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 150, 385-391. | 2.3 | 1 |
| 16 | Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 769-775. | 1.4 | 2 |
| 17 | Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973. | 3.3 | 31 |
| 18 | Results of COVID-minimal Surgical Pathway During Surge-phase of COVID-19 Pandemic. <i>Annals of Surgery</i> , 2020, 272, e316-e320. | 4.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570. | 1.8 | 32 |
| 20 | Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. <i>Reproductive Sciences</i> , 2019, 26, 600-608. | 2.5 | 14 |
| 21 | Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736. | 7.1 | 52 |
| 22 | PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019, 155, 144-150. | 1.4 | 28 |
| 23 | Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624. | 7.1 | 49 |
| 24 | PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164. | 1.4 | 13 |
| 25 | The incidence of microscopic adnexal metastatic disease in women with presumed early stage endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e17128-e17128. | 1.6 | 0 |
| 26 | Intraoperative evaluation of prophylactic hysterectomy and salpingoophorectomy specimens in hereditary gynaecological cancer syndromes. <i>Histopathology</i> , 2018, 73, 109-123. | 2.9 | 9 |
| 27 | <i>In Vitro</i> and <i>In Vivo</i> Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1003-1011. | 4.1 | 25 |
| 28 | A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591. | 1.4 | 53 |
| 29 | Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. <i>Journal of Clinical Oncology</i> , 2018, 36, 2044-2051. | 1.6 | 313 |
| 30 | Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853. | 7.0 | 18 |
| 31 | A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5536-5536. | 1.6 | 9 |
| 32 | Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17551-e17551. | 1.6 | 0 |
| 33 | Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. <i>Medical Oncology</i> , 2017, 34, 91. | 2.5 | 16 |
| 34 | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. <i>Gynecologic Oncology</i> , 2017, 146, 179-186. | 1.4 | 37 |
| 35 | Polymerase δ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152. | 1.4 | 55 |
| 36 | Dual-Targeting Nanoparticles for <i>In Vivo</i> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 323-333. | 4.1 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. <i>Gynecologic Oncology</i> , 2017, 147, 145-152. | 1.4 | 18 |
| 38 | The use of QuikClot combat gauze in cervical and vaginal hemorrhage. <i>Gynecologic Oncology Reports</i> , 2017, 21, 114-116. | 0.6 | 12 |
| 39 | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. <i>Clinical Cancer Research</i> , 2017, 23, 5836-5845. | 7.0 | 51 |
| 40 | Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e84. | 2.2 | 14 |
| 41 | SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/neu expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14009-e14009. | 1.6 | 1 |
| 42 | Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243. | 7.1 | 181 |
| 43 | SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1900-1909. | 4.1 | 55 |
| 44 | Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. <i>British Journal of Cancer</i> , 2016, 115, 303-311. | 6.4 | 27 |
| 45 | Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 99.e1-99.e8. | 1.3 | 17 |
| 46 | Mutational landscape of uterine and ovarian carcinosarcomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5589-5589. | 1.6 | 0 |
| 47 | Challenging Case of Postmenopausal Bleeding and Complete Urogenital Duplication. <i>American Journal of Case Reports</i> , 2016, 17, 331-336. | 0.8 | 0 |
| 48 | Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 123. | 8.6 | 29 |
| 49 | <i>Clostridium perfringens</i> enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. <i>International Journal of Cancer</i> , 2015, 137, 2618-2629. | 5.1 | 27 |
| 50 | Polymerase δ (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2015, 138, 11-17. | 1.4 | 68 |
| 51 | High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. <i>Journal of Contemporary Brachytherapy</i> , 2015, 1, 35-40. | 0.9 | 14 |
| 52 | Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. <i>Gynecologic Oncology</i> , 2015, 139, 112-117. | 1.4 | 27 |
| 53 | Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2519-2526. | 4.1 | 30 |
| 54 | Evaluation of the diagnostic accuracy of cervical biopsy and determination of associated risk factors for positive margin status in recurrent cervical dysplasia after loop or conization.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5609-5609. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.. Journal of Clinical Oncology, 2012, 30, e15526-e15526. | 1.6 | 1 |
| 56 | Targeting the upregulation of the AKT pathway and homologous recombination repair as a therapeutic strategy for epithelial ovarian cancer.. Journal of Clinical Oncology, 2012, 30, e13125-e13125. | 1.6 | 0 |
| 57 | Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).. Journal of Clinical Oncology, 2012, 30, 5099-5099. | 1.6 | 0 |
| 58 | Demographics of uterine serous cancer (USC) patients: A single institutional experience.. Journal of Clinical Oncology, 2012, 30, e15581-e15581. | 1.6 | 0 |
| 59 | A <i>KRAS</i> -Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research, 2010, 70, 6509-6515. | 0.9 | 135 |